Lilly's Cyramza fails in another Phase III study
This article was originally published in Scrip
Executive Summary
Eli Lilly's Cyramza (ramucirumab) has failed in the Phase III REACH trial in patients with hepatocellular carcinoma, casting further doubt on the therapeutic breadth of the anti-angiogenic agent.